Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19

Front Immunol. 2021 Jul 23:12:719115. doi: 10.3389/fimmu.2021.719115. eCollection 2021.

Abstract

Introduction: Loss-of-function TLR7 variants have been recently reported in a small number of males to underlie strong predisposition to severe COVID-19. We aimed to determine the presence of these rare variants in young men with severe COVID-19.

Methods: We prospectively studied males between 18 and 50 years-old without predisposing comorbidities that required at least high-flow nasal oxygen to treat COVID-19. The coding region of TLR7 was sequenced to assess the presence of potentially deleterious variants.

Results: TLR7 missense variants were identified in two out of 14 patients (14.3%). Overall, the median age was 38 (IQR 30-45) years. Both variants were not previously reported in population control databases and were predicted to be damaging by in silico predictors. In a 30-year-old patient a maternally inherited variant [c.644A>G; p.(Asn215Ser)] was identified, co-segregating in his 27-year-old brother who also contracted severe COVID-19. A second variant [c.2797T>C; p.(Trp933Arg)] was found in a 28-year-old patient, co-segregating in his 24-year-old brother who developed mild COVID-19. Functional testing of this variant revealed decreased type I and II interferon responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist imiquimod, confirming a loss-of-function effect.

Conclusions: This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors. A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but also enables pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions.

Keywords: COVID-19; SARS-CoV-2; TLR7; genetic screening; host genetics; immunodeficiency.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amino Acid Substitution
  • COVID-19 / genetics*
  • COVID-19 / immunology
  • COVID-19 / pathology
  • Genetic Testing
  • Humans
  • Male
  • Middle Aged
  • Mutation, Missense*
  • Risk Factors
  • SARS-CoV-2*
  • Severity of Illness Index
  • Toll-Like Receptor 7 / genetics*
  • Toll-Like Receptor 7 / immunology

Substances

  • TLR7 protein, human
  • Toll-Like Receptor 7